In this study, we performed a proteomic analysis to characterize differences in protein expression between KRASG12D secondary-mutant cell lines and KRASG12D single-mutant cell lines. Through systematic data analysis, we identified the key signaling pathways and regulatory proteins associated with resistance to KRASG12D inhibitors, and further explored combination therapeutic strategies to overcome drug resistance.